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Abstract
Background: Herb/Dietary Supplements (HDS) are the most popular Complementary and Alternative Medicine (CAM)
modality used by cancer patients and the only type which involves the ingestion of substances which may interfere
with the efficacy and safety of conventional medicines. This study aimed to assess the level of use of HDS in cancer
patients undergoing treatment in the UK, and their perceptions of their effects, using 127 case histories of patients
who were taking HDS. Previous studies have evaluated the risks of interactions between HDS and conventional drugs
on the basis on numbers of patient using HDSs, so our study aimed to further this exploration by examining the actual
drug combinations taken by individual patients and their potential safety.
Method: Three hundred seventy-five cancer patients attending oncology departments and centres of palliative care at
the Oxford University Hospitals Trust (OUH), Duchess of Kent House, Sobell House, and Nettlebed Hospice participated
in a self-administered questionnaire survey about their HDS use with their prescribed medicines. The classification
system of Stockley’s Herbal Medicine’s Interactions was adopted to assess the potential risk of herb-drug interactions
for these patients.
Results: 127/375 (34 %; 95 % CI 29, 39) consumed HDS, amounting to 101 different products. Most combinations were
assessed as ‘no interaction’, 22 combinations were categorised as ‘doubt about outcomes of use’, 6 combinations as
‘Potentially hazardous outcome’, one combination as an interaction with ‘Significant hazard’, and one combination as
an interaction of “Life-threatening outcome”. Most patients did not report any adverse events.
Conclusion: Most of the patients sampled were not exposed to any significant risk of harm from interactions with
conventional medicines, but it is not possible as yet to conclude that risks in general are over-estimated. The incidence
of HDS use was also less than anticipated, and significantly less than reported in other areas, illustrating the problems
when extrapolating results from one region (the UK), in one setting (NHS oncology) in where patterns of supplement
use may be very different to those elsewhere.
Keywords: Complementary medicines, Alternative medicines, Cancer, Herb-drug interactions, Herbal medicines,
Dietary supplements, Conventional medicines
Background
Many studies have recorded a high use of Herbal/Dietary
Supplements (HDS) by cancer patients. The MD Anderson
Cancer Centre, in USA, reported that 52 % of their cancer
patients had used at least one form of Complementary and
Alternative Medicine (CAM), and 77 % of those were using
herbs and vitamins [37]. Between 25 and 47 % of ethnic
Chinese cancer patients living in North America relied on
herbal preparations as part of their cancer treatment [6]. In
the US, a survey showed that about 63 % of outpatient can-
cer patients used HDS [35]. In the UK, a systematic review
of 11 papers investigating the use of herbal medicines by
cancer patients found the prevalence of herbal medicines
use varied from 3.1 to 21.8 % among adults and from 4.1 to
20 % in paediatric patients [11].
In the absence of good efficacy data for most HDS,
and given their popularity with patients, the most urgent
current concern is assuring their safety (WHO [32]).
Some herbal medicines have been extensively studied
and there is clinical evidence for both potential benefits
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and risks (e.g. Hermann and von Richter [13]). Many
pre-clinical studies which have been carried out to
evaluate the safety of HDS in combination with licensed
or prescribed drugs are not supported by the clinical evi-
dence when carefully assessed (e.g. [17]).
Very few studies have been conducted to evaluate the
safety of herbal medicines and their combinations used
as self-medication, or as recommended by herbal medi-
cine practitioners (Heinrich et al. [12]). The potential for
interactions between herbs and other medicines may be
higher due to the large number of components in the
herb, compared to the single active substance of conven-
tional medicines [9]. In addition, a single herb or prod-
uct may be used to treat several conditions, and
different herbs may be used to treat the same illness,
making interactions difficult to interpret accurately.
There is another obstacle, which is the lack of detail in
many reports: in one study, about 2000 combinations
from 4 electronic databases were screened to assess the
probability of interaction, and of 108 cases identified as
potential interactions, 70 % did not provide adequate
data for this to be achieved. Only 13 % of cases were
identified as ‘well-documented’, but warfarin was the
conventional medicine most commonly involved, and St
John’s wort was the herb cited in most interactions [9].
Assessing the safety and efficacy of HDS use is further
complicated because many studies have reported that
cancer patients often do not tell their healthcare pro-
viders about their CAM use [2, 34]. Ernst [7] reported
that only 25 % of cancer patients using HDS received
advice from their doctors and that communication about
HDS was virtually non-existent. Side effects and drug in-
teractions were the most common concerns expressed
by the researchers [14, 21, 23, 29] but to date, many doc-
umented potential interactions have been extrapolated
from in vitro or animal studies, or have not been
described in an appropriate context [24, 34].
There are certainly herb-drug combinations which
may result in serious consequences in cancer patients.
For example, the concurrent use of enzyme inducers
such as St. John’s wort (Hypericum perforatum) can
affect many drugs: St John’s wort has been shown to
cause a 44 % reduction in the time of imatinib (an anti-
cancer drug) remains at therapeutic blood levels [20].
The aim of this study was to therefore investigate real-
life HDS use by cancer patients and their experiences of
benefit or harm. An individual assessment for each
patient was used to assess the risk posed by the drug
regime and HDS consumption.
Methods
Questionnaire distribution
Self-administered questionnaire surveys comprising open-
ended and closed-ended questions (see supplementary
information) were posted to eligible participants being
treated for cancer at the Oxford University Hospitals
Trust (OUH) and centres of palliative care at the Sobell
House, Duchess of Kent House, and Nettlebed Hospice,
located in the Thames Valley Area, UK. Cancer patients
were identified by oncology and palliative care consultants
at each study centre based on the following inclusion
criteria: aged above 18 years, able to speak English, cur-
rently receiving treatment for their diagnosed cancer, and
able to understand and fill out the questionnaire. Patients
were excluded from the study if consultants felt they were
unable to participate on medical grounds. All responses
were anonymous unless the patients chose to provide con-
tact details in order to receive feedback.
The questionnaire asked patients to record all of the
conventional medicines prescribed by their GP, oncolo-
gist or palliative care specialist and, if they also took
HDS, we asked them to list all products they had taken
at the same time as their usual drug regime. Patients
were not asked to select from a prepared list in order to
explore the variety of products used and to see which
substances they actually considered to be HDS. We also
asked about their perceived experiences from these HDS
use in order to retrospectively identify any experiences
of benefit or harm. data such as sources of HDS and ad-
vice, and if they had taken HDS before being diagnosed,
were gathered for separate analysis.
Questionnaires were posted to eligible participants and
completed questionnaires returned to the study team in
reply-paid pre-addressed envelopes over the study period
(August 2013 – January 2014). Response rates were
maximised by encouraging patients to complete and
return the questionnaire even if they took no HDS; and
patients who were taking HDS were offered the oppor-
tunity to receive feedback on the safety of their use. Due
to financial constraints a single mailing was used. Where
patients indicated that they would like feedback on their
use of HDS, they supplied contact details, and a review
letter providing information about the safety of the com-
bination they were using was sent. If any risks were
identified patients would be advised to contact their
oncology or palliative care team to discuss in more
detail, in accordance with the Ethical approval protocol.
Assessing potential interactions between HDS and
conventional medicines
Combinations of HDS and conventional medicines re-
ported by participants were assessed using the system of
classification or the potential for interaction and severity
as described in Stockley’s Herbal Medicine’s Interactions
(SHMI) (2013). A literature search was also carried out
in case very recent data had been published or if a sup-
plement was not included. SHMI is a comprehensive,
evidence-based reference for interactions between herbal
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medicines/dietary supplements and conventional medi-
cines which is regularly updated on-line. It rates interac-
tions in three different categories:
 Action: whether or not any action needs to be taken
to address the interaction.
 Severity: the likely effect on a patient of an unmanaged
interaction.
 Evidence: the weight of the available evidence.
On the basis of these, one of five symbols is used to
describe the combination, ranging from; ‘no interaction’,
‘doubt about outcomes of use’, ‘potentially hazardous
outcomes’, ‘significant hazard’ and to ‘life-threatening
outcomes’. These symbols are defined as follows:
No interaction: the interaction has not been
conclusively demonstrated or is not considered to
be clinically significant.
Doubt about outcomes of use: there is doubt
about the existence or severity of a suspected
interaction, but patients may need some guidance
about possible adverse effects, and/or monitoring
should be considered.
Potentially hazardous outcome: there may be a
potentially hazardous interaction, but the data is
poor or sparse and conclusions are difficult to draw.
Significant hazard: current use may result in
significant hazard to patients and so careful
monitoring or dosage adjustment is needed.
Life-threatening outcome: the interaction is life-
threatening, and concurrent use should be avoided.
If SHMI and a literature review raised no concerns, in
that no reports of interactions between the drugs, and in
the case of the herb, a related herb containing similar
constituents, were cited, the combination was assessed
as ‘no interaction’. If the combination showed evidence
of similar pharmacological activity, for example if the
drug and the supplement were known to both possess
anti-hypertensive activity, then the combination was
categorised as ‘doubt about outcomes of use’. Assess-
ments of interactions between HDS were made, as well
as between supplements and conventional medicines, as
these had not previously been carried out.
Data analysis
A respondent was defined as a user of HDS if they
reported that they had used herbal medicines or dietary
supplements. Responses were categorised according to
patient sociodemographic, cancer diagnosis, previous
use of HDS, specific HDS being taken, prescribed
medicines taken concurrently, and the individual HDI
assessments. The data obtained from the questionnaires
were entered into the (SPSS V.21) to calculate summary
statistics, for the proportions of participants in each cat-
egory, with 95 % confidence intervals. All data entry was
double checked. HDS use, conventional medicine use,
and HDS-conventional combinations presented as me-
dian and the interquartile range (IQR), for each of these
measures.
Results
Three hundred seventy-five out of 1457 (26 %; 95 % CI
24, 28) cancer patients who were approached, having
been identified by oncology and palliative care consul-
tants at each study centre, participated in the study. Of
these responders, 127 out of 375 (33.9 %; 95 % CI: 29,
38) reported using HDS, before or after their diagnosis
with cancer. The other 235 responders did not use HDS,
but gave details of their demographics, including their
diagnoses. In our sample, females (74; 58.3 %) used HDS
slightly more than males (53; 41.7 %); however, the re-
sponders were also predominantly female. Patients aged
60 years and above (74; 58.3 %) used HDS more than
other age groups. Breast, prostate, and melanoma cancer
patients were the most commonly HDS users (40;
31.5 %), (26; 20.5 %), and (22; 17.3 %) respectively. The
demographic characteristics of participants, both HDS
users and non-users, are shown in Table 1.
HDS users reported 1255 herb-drug combinations, for
a median rate of 11.5 (IQR, 2.5–14) per user. Overall,
101 different HDS were used concurrently with other
medicines, for a median 1.5 (IQR, 1–4) per user, with
167 different conventional drugs, for a median of 1
(IQR: 1–6) per user. Glucosamine, cod liver oil, vitamins,
omega 3 fatty acids, green tea, garlic, selenium, and fish
oil were the most common HDS taken; the numbers of
patients reporting these and others are shown in Table 2.
Cod liver oil, omega-3 fatty acids and fish oil are related
products but there are some differences in their compos-
ition and the way they are marketed, and patients cited
them by product name.
We also examined the HDS taken by patients with
specific cancer types, to see if any group showed a pref-
erence for a specific HDS, and as such might be at par-
ticular risk. Breast cancer patients reported taking the
widest range of DHS, citing over 24 different types of
product, as shown in Table 3, and the most popular
HDS were similar to those for the overall cohort of
responders, i.e. cod liver oil, vitamins, glucosamine,
omega 3 fatty acids and green tea. Prostate cancer patients
reported using 15 different HDS; the most popular again
being cod liver oil, glucosamine, vitamins, green tea and
omega 3 fatty acids, as shown in Table 4. Melanoma
patients reported using 9 different HDS products, again
conforming to the general pattern of the responders
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overall, shown in Table 5. Renal, brain, gastro-oesophageal,
pancreatic and bowel cancer patients also reported using a
variety of different HDS but there were insufficient num-
bers of each diagnosis to analyse separately.
Interactions between HDS and conventional medicines
Most of the herb-drug combinations (1225; 97.6 %) were
categorised as ‘no interaction’, 22 combinations were
categorised as interactions with “doubt about outcomes
of use”, 5 combinations as interactions with “Potentially
hazardous outcome”, one combination as an inter-
action with “Significant hazard”, and one combination
as an interaction with “Life-threatening outcome”, as
shown in Table 6.
Eighty-seven (75.7 %) HDS users reported that they
had experienced benefits, with 82 attributing these to
HDS. Only 4 (3.4 %) patients experienced problems, 2
believing they were caused by HDS; however, no adverse
drug events (ADE) were recorded. 28 (24.7 %) patients
responded that they had not experienced either benefit
or harm during their HDS usage. 8 (6.3 %) patients had
reported that they used HDS but did not report their
experiences about HDS usage.
The HDI assessments showed that 11 HDS were
involved in some risk of interaction: cod liver oil, St
John’s wort, omega-3 oils, glucosamine, senna, green tea,
EPA (eicosapentaenoic acid), fish oil, garlic, ginkgo, and
evening primrose oil. Of the conventional medicines, 20
drugs were involved: aspirin, dipyridamole, clopidogrel,
warfarin, dalteparin, heparin, insulin, omeprazole,
Table 1 Demographic characteristics and CAM practices used
by patients
Characteristic HDS users
(out of 127)
(%; 95 % CI)
Non-HDS users
(out of 235)
(%; 95 % CI)
Age
20–30 2 (1.6; 0.4, 5.5) 0
31–40 6 (4.7; 2.2, 9.9) 8 (3.4; 1.7, 6.6)
41–50 14 (11.0; 6.7, 17.7) 27 (11.5; 8.0, 16.2)
51–60 31 (24.4; 17.8, 32.6) 44 (18.7; 14.3, 24.2)
61–70 50 (39.4; 31.3, 48.1) 77 (32.8; 27.1, 39.0)
> 70 24 (18.9; 13.0, 26.6) 79 (33.6; 27.8, 39.8)
Gender
Male 53 (41.7; 33.5, 50.4) 132 (56.1; 49.8, 62.4)
Female 74 (58.3; 49.6, 66.5) 103 (43.9; 37.6, 50.2)
Cancer diagnosis
Breast cancer 40 (31.5; 24.1, 40.0) 51 (21.7; 16.9, 27.4)
Prostate cancer 26 (20.5; 14.4, 28.3) 35 (14.9; 10.9, 20.0)
Melanoma 22 (17.3; 11.7, 24.8) 55 (23.4; 18.4, 29.2)
Renal cancer 4 (3.2; 1.2, 7.8) 18 (7.6; 4.9, 11.8)
Brain cancer 8 (6.3; 3.2, 11.9) 5 (2.1; 0.9, 4.9)
Gastro-oesophageal
cancer
3 (2.4; 0.8, 6.7) 12 (5.1; 2.9, 8.7)
Pancreatic cancer 3 (2.4; 0.8, 6.7) 10 (4.3; 2.3, 7.7)
Bowel cancer 6 (4.7; 2.2, 9.9) 11 (4.7; 2.6, 8.9)
Othera 15 (11.8; 6.9, 19.0) 30 (12.8; 9.1, 17.6)
Healthcare type
Oncology 110 (86.6; 79.6, 91.5) 211 (89.8; 85.3, 93.0)
Palliative 17 (13.4; 8.5, 20.4) 24 (10.2; 6.9, 14.7)
aCancer diagnosis grouped based on the frequency. Other cancer types include
non-Hodgkins lymphoma, mesothelioma, adenocarcinoma, thymoma, bladder,
bone, testicular, bile duct, stomach, throat, lung, liver, buccal, omentum, ampullary
cancer, ovarian, bone marrow, tonsil, anal, tongue and neuroendocrine cancers
Table 2 Frequencies of specific Herbal and Dietary Supplements
(HDS) cited by cancer patients
Supplement cited No taking
the named
HDS
As % of total
responders
(127)
Glucosamine 28 22.1
Cod liver oil 26 20.5
Multivitamins 21 16.5
Vitamin C 17 13.4
Omega fatty acids; Vitamin D 15 11.8
Green tea 12 9.4
Fish oil, Garlic, Selenium 9 7.1
Chamomile; Co Enzyme Q10 8 6.3
Calcium 7 5.5
Zinc 6 4.7
Echinacea; Evening primrose; Peppermint;
Turmeric
5 3.9
Cranberry; Flaxseed; Ginger; Vitamin B 4 3.1
Aloe Vera; ‘Herbal tea’ (not specified); Iron;
Magnesium; Probiotics; Senna; Wheatgrass;
Ginkgo biloba; St John’s wort
3 2.4
Astragalus; Blue/green algae; Bromelain;
Chondroitin; Ispaghula; Kelp; Lycopene;
Plant sterols; Saw palmetto; SuperGreens®;
Vitamin B12; Vitamin E
2 1.6
Kalms; Lecithin; Milk thistle; Mistletoe;
Starflower oil; Pycnogenol®; Soursop juice;
Vegepa E-EPA®; Melatonin, Osteocare®;
Brewer’s yeast; Menopace®; Grapeseed extract;
Phyto power®, Quercetin; Shiitake extract;
Digest plus®, L-glutathione; Sheep sorrel root;
Tea-tree oil; Red clover; Pomegranate; Propolis;
Wormwood; Liver flush®; Bach remedies®;
Chlorella; BioCare® acidophilus; BioCare®
antioxidants; Artichoke; Acai; Lutein;
Sea buckthorn; Raspberry leaf; Rooibos tea;
Blackcurrant; Ginseng; Manuka honey, Vanilla;
Potter’s cough pastilles; POMI-T; Fennel,
Devil’s Claw, Coconut; Krill oil, Indole-3-carbinol;
Boswellia, Apricot kernels; Serenagen Sleep®;
Carotenoid complex; Flavonoids; Cruciferous
plus®; Formula IV®; Ocuvite®; ‘Chinese herbal
tea’ (not specified).
1 0.8
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sertraline, amitriptyline, risperidone, epirubicin, doxo-
rubicin, paracetamol, co-codamol, amlodipine, lisinopril,
atorvastatin, simvastatin, and pravastatin.
Interactions between different HDSs
All combinations of HDS were deemed safe overall in
the circumstances in which they were used, and the few
cases which may have given cause for serious concern
had already been resolved (see Table 7), usually because
the patient had stopped taking the particular supplement
before completing the questionnaire. Some herbal medi-
cines have intrinsic properties which may case HDIs in
large doses: for example, stimulant laxatives such as
senna alter intestinal transit and in large doses or over a
period of time may affect the absorption of any herb or
drug taken at the same time, but these are predictable
effects and can be avoided. The other issue is that sup-
plements containing similar constituents may be taken
together, for example evening primrose oil and star
flower oil, which are both sources of gamolenic acid;
however, as this compound is relatively safe the combin-
ation is unlikely to be harmful.
Discussion
In a recent systematic review, Alsanad et al. [3] sought
to determine the proportion of cancer patients deemed
to be at risk from HDIs from the actual combinations
they were taking, but only 5 studies were found which
explored this issue specifically [8, 18, 20, 31, 37]. HDS
are the most popular form of CAM used by cancer
Table 3 Frequencies of specific HDS use by cancer diagnosis.
Specific HDS use by breast cancer (BC) patients and comparison
with overall frequency of use
Supplement No of BC patients reporting each HDS
(% out of 40 BC patients; % use overall
in 127 HDS users, from Table 1)
Cod liver oil 9 (22.5; 20.5)
Vitamin D 8 (20; 11.8)
Glucosamine 7 (17.5; 22.1)
Multivitamins 7 (17.5; 16.5)
Omega-3 fatty acids; 5 (12.5; 11.8)
Vitamin B 5 (12.5; 3.1)
Green tea 4 (10; 9.4)
Calcium 4 (10; 5.5)
Chamomile; 3 (7.5; 6.3)
Co-enzyme Q10; 3 (7.5; 6.3)
Fish oil; 3 (7.5; 7.1)
‘Herbal tea’ (not specified) 3 (7.5; 2.4)
Wheatgrass 3 (7.5; 2.4)
Aloe vera 2 (5; 2.4)
Bromelain 2 (5; 1.6)
Cranberry 2 (5; 3.1)
Evening primrose 2 (5; 3.9)
Garlic; 2 (5; 7.1)
Kelp 2 (5; 2.4)
Peppermint 2 (5; 3.9)
Selenium 2 (5; 7.1)
Turmeric 2 (5; 3.9)
Vitamin C 2 (5; 13.4)
Zinc 2 (5; 4.7)
Table 4 Frequencies of specific HDS use by cancer diagnosis.
Specific HDS use by prostate cancer (PC) patients and comparison
with overall frequency of use
Supplement No of PC patients reporting each HDS
(% out of 26 PC patients; % use overall
in 127 HDS users, from Table 1)
Cod liver oil 7 (27; 20.5)
Glucosamine 6 (23; 22.1)
Multivitamins 6 (23; 16.5)
Vitamin C 5 (19.2; 13.4)
Green tea 4 (15; 9.4)
Omega-3 fatty acids 3 (11.5; 11.8)
Selenium 3 (11.5; 7.1)
Co-enzyme Q10 2 (7.7; 6.3)
Evening primrose oil 2 (7.7; 3.9)
Fish oil; 2 (7.7; 7.1)
Garlic; 2 (7.7; 7.1)
Lycopene 2 (7.7; 1.6)
Saw palmetto 2 (7.7; 1.6
Vitamin B 2 (7.7; 3.1
Zinc 2 (7.7; 4.7)
Table 5 Frequencies of specific HDS use by cancer diagnosis.
HDS reported use by melanoma patients and comparison with
overall frequency of use
Supplement No of ML patients reporting each HDS
(% out of 22 ML patients; % use overall
in 127 HDS users from Table 1)
Glucosamine; 12 (54.5; 22.1)
Cod liver oil 10 (45.4; 20.5)
Vitamin D 7 (31; 11.8)
Multivitamins 6 (27.3; 16.5)
Green tea 4 (18.2; 16.5)
Omega-3 fatty acids 3 (13.6; 11.8)
Selenium 3 (13.6; 7.1)
Calcium 2 (9.1; 5.5)
Zinc 2 (9.1; 4.7)
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Table 6 Assessment of Herb/Dietary Supplements (HDS) -Conventional Medicine (CM) Interactions
HDS CM [no of patientsa] Possible interactions based on previous reports or theoretical grounds and their assessmentb
HDI Category: “doubt about outcomes of use”
Cod liver oil Aspirin [4]
Clopidogrel [1]
Warfarin [1]
Simvastatin [3]
Atorvastatin [2]
Rosuvastatin [1]
Heparin [1]
Both have antiplatelet properties, but the combination did not cause any problems in any of the 4
patients and no previous clinical reports are available.
Both have antiplatelet properties, but the combination did not cause any problems and no previous
clinical reports are available.
Cod liver oil and warfarin both increase INR. This combination has not caused any problems in the
patient, no clinical reports are available, and was assessed as unlikely to be harmful.
Both have cholesterol-lowering properties. The combination did not cause problems in the patients.
As for simvastatin.
As for simvastatin
Cod liver oil has antiplatelet effects and increase INR, and heparin is an anticoagulant, but the but
the patient did not experience problems, possibly due to being monitored for heparin effects.
Glucosamine Insulin [1]
Doxorubicin [1]
Epirubicin [1]
Paracetamol [4]
Endogenous glucosamine is involved in glucose metabolism but studies suggest that it is unlikely
to affect diabetic control in patients taking insulin.
Glucosamine has produced a modest resistance to doxorubicin in colon and ovary cancer cells in
vitro but the effect has not been confirmed in vivo, and was assessed as unlikely to be harmful.
As for doxorubicin, and therefore assessed as unlikely to be harmful.
Glucosamine sulphate may reduce the efficacy of paracetamol (2 previous reports), by increasing
paracetamol sulfate conjugation, but the combination did not cause any problems in our 4 patients.
Omega 3 Dipyridamole [1]
Aspirin [4]
Simvastatin [1]
Pravastatin [1]
Omega-3 oils and dipyridamole all have antiplatelet properties. However, this combination did not
cause ADEs in the patient, and was assessed as unlikely to be harmful.
Omega-3 oils and aspirin both have antiplatelet properties. However, it did not cause ADEs in the
patient, no other clinical reports are available so it was assessed as unlikely to be harmful.
Omega-3 oils and simvastatin have cholesterol-lowering properties. However, the combination did
not cause ADEs in the patient.
As above (for simvastatin) as omega-3 oils and pravastatin have cholesterol-lowering properties.
Fish oil Simvastatin [2]
Warfarin [1]
Fish oil and simvastatin both have cholesterol-lowering properties. This combination did not cause
any problems in the two patients taking it.
Fish oil and warfarin both increase INR, but the patient did not experience problems, possibly due
to being carefully monitored for warfarin effects.
Garlic Atorvastatin [1]
Heparin [1]
Garlic and statins lower plasma cholesterol but the but the patient did not experience problems.
Garlic has antiplatelet effects and increases INR, and heparin is an anticoagulant, but the patient
did not experience problems, possibly due to being carefully monitored for heparin effects.
Senna Paracetamol [3] It has been suggested that senna may reduce the absorption of paracetamol based on weak
experimental evidence but our 3 patients did not experience problems.
St John’s wort Omeprazole [1] St John’s wort may lower plasma concentrations of omeprazole but there are no clinical reports.
Eicosapentaenoic
acid (EPA)
Dalteparin [1] EPA has antiplatelet properties and may add to the effects of anticoagulants such as dalteparin.
However, the patient has not experienced any adverse effects.
HDI Category: “Potentially hazardous outcome”
St John’s wort Amitriptyline [1] St John’s wort may lower plasma concentrations of amitriptyline but no harmful clinical reports
have been recorded and the patient did not experience any problems.
Green tea Clopidogrel [1] It has been suggested that green tea may have additive effects with antiplatelet drugs such as
clopidogrel but no clinical reports are available and the combination was assessed as not harmful.
Garlic Lisinopril [1] A single report of garlic with lisinopril in 1996 suggested the combination lowered blood pressure
more than expected, but the patient did not experience any problems and garlic is taken widely.
Ginkgo Omeprazole [1]
Risperidone [1]
A clinical study found that ginkgo modestly induced the metabolism of omeprazole but a later
study concluded that it was not clinically relevant. The patient reported no harmful effects.
Priapism was previously reported in a patient taking risperidone and ginkgo. Risperidone alone
causes priapism (rarely) and our patient did not experience this.
HDI Category: “Significant hazard”
St-John’s Wort Amlodipine [1] St-John’s Wort is an inducer of CYP3A4 so the combination may lower plasma concentrations of
amlodipine, decreasing hypotensive effects. However, the patient was being checked regularly and
reported no ADEs, so the combination was assessed in retrospect as not harmful.
HDI Category: “Life-threatening outcome”
St-John’s Wort Sertraline [1] The combination of St John’s wort and sertraline may lead to serotonin syndrome (reported in 4
previous studies). This combination is contra-indicated but the patient was no longer taking it.
aThis is the number of patients exposed to the particular combination. In some cases, patients were also taking other recorded combinations
bThe potential interactions and previous reports are taken from Stockley’s Herbal Medicine Interactions, except where not included in that reference, in which
case other sources are given
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patients and have the greatest potential to cause harm,
not only by causing adverse effects or by inappropriate
use, but also by interacting with conventional medicines.
There is thus a need to identify individual cancer
patients taking HDS who might be at risk from HDIs,
rather than making a global risk assessment based on
population studies.
Our HDS safety assessments examined the actual
combinations taken by each patient. Several combina-
tions which would have been assessed as harmful on
theoretical grounds did not actually produced an adverse
effect in practice. It should be emphasised that our HDI
assessments were not an estimation of risk, as originally
intended, since they were done after the patient had taken
the combination, and no patient reported any ADE.
Instead it is an exploration of the levels of use of specific
HDS with prescribed and/or licensed medicines and the
patients’ experiences of taking these combinations.
Certain combinations were retrospectively judged as
not clinically significant, despite having been previously
categorised in other resources as carrying some risk, for
example ‘Doubt about outcomes of use’, ‘Potentially haz-
ardous outcomes’, or ‘Significant hazard’ as detailed in
the Table 2. Our assessments also recorded the incidence
of patients taking combinations which have been previ-
ously been judged to be inadvisable, but which did not
result in a harmful outcome. In these cases, categorised
as ‘Potentially hazardous outcomes’, ‘Significant hazard’
and ‘Life-threatening outcomes’, the patient would have
been advised NOT to take the combination if they had
enquired beforehand. No ill effects were reported, but
whether this is because the risk is indeed theoretical or
because the patient was simply fortunate, cannot be
determined in a study of this type.
Cod liver oil, St John’s wort, omega 3 oils, glucosa-
mine, senna, green tea, EPA (eicosapentaenoic acid), fish
oil, garlic, ginkgo, and evening primrose were the HDSs
involved in the risk of interaction with the conventional
medicines: aspirin, dipyridamole, clopidogrel, warfarin,
dalteparin sodium, heparin, insulin, omeprazole, sertra-
line, amitriptyline, risperidone, epirubicin, doxorubicin,
paracetamol, co-codamol, amlodipine, lisinopril, atorva-
statin, simvastatin, and pravastatin. Many anti-cancer
drugs are metabolised by cytochrome P450 (CYP)
enzymes, and especially CYP3A4, [22]. The interaction
occurs if the HDS induces or inhibits the metabolizing
enzymes or affects the drug transporter of the drug [19],
but these should return to normal levels once the HDS
use ceases [20].
A number of HDSs, such as ginkgo biloba, dan shen,
liquorice, ma huang, have been implicated in reports of
interaction with conventional medicines, and the drugs
involved (warfarin, protease inhibitors and some anti-
cancer drugs) have well-documented interaction profiles
with other drugs [9, 15, 33]. St John’s wort has been
involved in many HDI reports with other drugs [34] in-
cluding anticancer agents, and for example, its inter-
action with imatinib occurs due to both induction of the
metabolic enzymes CYP3A4 and CYP2C19 and the
transporter of imatinib, leading to a lowering of plasma
levels [27]. Therefore, it should certainly be avoided in
cancer patients as a precaution [15, 25]. On the other
hand, cancer patients often use garlic as a supplement,
and although it has been suggested that garlic may
alter metabolism of anti-cancer drugs such as doce-
taxel, a recent study found no in vitro interaction
[10]. A risk of gastrointestinal bleeding has also been
associated with garlic use [1, 28]: again, garlic is
Table 7 Potential risks associated with the use of some HDSs used by cancer patients
HDS or combination of concern
[no of patients exposed to potential risk]
aComments on previous reports and assessment of risk
Soursop (Graviola) [1] Herbal products made from the leaves or bark of soursop are sold as alternative treatments for cancer with
no clinical evidence but on the basis of experimental studies showing selective cytotoxicity in some cancer
cell lines. Their use is associated with atypical Parkinson’s disease, due to the content of acetogenins
(especially annonacin-1, a mitochondrial complex I inhibitor) and the neurotoxic alkaloids reticuline and
N-methylcoculaurine [4]. These compounds are not present to any great extent in the juice, which the
patient had been drinking, so this practice was assessed as not harmful.
Evening primrose oil and Star flower
oil in combination [1]
Evening primrose and star flower oils are both sources of gamolenic acid; however, gamolenic acid is a
relatively safe substance and the combination is unlikely to be harmful.
Senna [3] Senna increases intestinal transit and large doses can reduce the absorption of a drug. However, the 3
patients were taking opioids (codeine 2; tramadol 1) which cause constipation, and thus needed senna to
counteract their effects.
Fish oil/cod liver oil/EPA/omega-3 fatty
acid with garlic in combination [5]
The combination of fish oils (and by inference, unsaturated fatty acids) with garlic has been reported to
have increased lipid lowering effects, but these are thought to be generally beneficial.
Apricot kernels [1] Apricot kernels are promoted as an alternative treatment for cancer with no evidence of efficacy. They contain
a glycoside called amygdalin which is toxic in large quantities as it releases cyanide gas, and poisoning has
been reported [26]. The patient had not experienced any ADEs and had stopped taking the product, so
intervention was not deemed appropriate.
aComments on previous reports are taken from Stockley’s Herbal Medicine Interactions, except where not included, in which case other references are given
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consumed by many people as food, and no ADEs re-
ports have been published to date, so is unlikely to
cause harm.
Cancer patients may sometimes feel the need for a
mild sedative or tranquilliser, and the herb valerian is a
very popular ingredient in herbal sleeping and relaxation
products. Valerian has been said to “interfere in an
unwanted way with oncological cancer therapy” or “can
diminish the efficacy of cancer therapeutics” (e.g. Sloan
Kettering Center 2012, cited by [17]). Kelber et al. exam-
ined the pre-clinical studies and concluded that ‘avail-
able animal and human pharmacodynamic studies did
not verify any interaction potential’ and ‘there is no spe-
cific evidence questioning their safety, also in cancer pa-
tients’ [17]. In our study, the incidence of HDS use was
less than anticipated, and significantly less than reported
in other areas, again illustrating further problems when
extrapolating results from one region (the UK), and in
one setting (NHS oncology), where patterns of supple-
ment use may be very different to those elsewhere.
Cancer patients regard HDS highly, as shown by many
studies, and also the volume of sales of these products
(Chrystal et al. [5]). The HDS identified in our study
were used by patients with a broad range of diagnoses,
and none was used only by a those in a particular group.
Certain HDS were more popular in certain groups, as
shown in Tables 3, 4 and 5, but the sample size was in-
sufficient to draw any firm conclusions on these. Thus it
is necessary to deal with the issue of HDIs in a realistic
and pragmatic manner, because over-reaction to poten-
tial dangers and inaccuracies in reporting may cause pa-
tients to ignore even good advice on this subject.
Another important issue is how the lack of evidence of
HDS safety and efficacy should be addressed, as well as
how the current evidence should be interpreted. In other
words, there is a strong demand for an appropriate and
robust framework for evaluating HDS safety and efficacy
at different levels of patients’ needs, which includes so-
cial, epidemiological, and clinical studies [36].
It is crucial to alert and educate patients about the possi-
bility of HDIs but it would be counter-productive to scare
them with unfounded negative speculation at a time when
they are particularly vulnerable. Clinicians should feel able
to discuss any treatments that might be helpful, as well as
warning of possible dangers, since there is a lack of aware-
ness of these [30], and given the wide use of HDS, they need
to be better informed. ADEs and HDIs related to HDS can
be reported in the same way as adverse reactions to
conventional medicines, in the UK via the Yellow
Card Scheme, but happens infrequently. Whether this
is because ADEs involving HDS are unusual or be-
cause of under-reporting is not clear, but if improved,
would go some way to increasing the accuracy of the
risk assessment of these combinations [33].
Conclusion
Our study revealed that more than 100 different HDS
were being used to manage cancer and other health is-
sues, and our assessment of the numerous combinations
of these with conventional medicines and other HDS
showed that the majority of patients were not at great
risk of HDIs. Most previous studies have assessed the
safety of HDS use theoretically and without exploring
the actual products used by cancer patients. Much of the
available drug interaction evidence is based on pre-
clinical studies, which do not always translate well into
clinical experience, and in many case reports, data re-
garding the identity, composition, purity and even the
dose of the herb is incomplete [16]. This may give an
overestimate of risk based on speculation. Our survey
was retrospective and most of the patients surveyed had
been taking the combination for some time without ex-
periencing any adverse events, but the sample size was
not sufficient to conclude that the risk fir some supple-
ments has been inflated on this evidence. As it would be
unethical to deliberately give patients any combinations
of drugs (including herbs) which may cause harm, the
only feasible method of assessing risk at present is to
collect evidence retrospectively from patients who are
using or have used HDSs. This will provide documented
evidence upon which healthcare professionals and can-
cer patients can based their judgement as to whether
taking a particular HDS is advisable or not.
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